Utilizing the Gibco™ CTS™ Rotea™ System, a Versatile Closed Manufacturing System, for Cell and Gene Therapy Development
Cell and gene therapy involves extracting cells, protein or genetic material from a patient or donor and altering them to provide a highly personalised therapy. These therapies have shown potential to offer longer-lasting effects than traditional methods.
In this talk, we will discuss the value of moving towards modular and automated, closed-system technologies designed to enable scalable and cost-effective manufacturing. Also learn more about how ViaCyte, a clinical stage regenerative medicine company, is focused on delivering novel stem cell-derived pancreatic cell replacement therapies as a functional cure for diabetes. Producing the stem cells required to support development of these therapies and future commercial demand requires an aggressive scale-up effort.
Watch this webinar to learn about:
The current challenges in cell therapy manufacturing
How the Gibco CTS Rotea system utilizes the proven counterflow centrifugation method to enable exceptional performance for cell therapy development
How the Rotea system is processing stem cell aggregates in bioreactors as part of a cell therapy scale-up effort
